Bortezomib, Lenalidomide and Dexamethasone (VRd) With Belantamab Mafodotin Versus VRd Alone in Transplant Ineligible Multiple Myeloma

Condition:   Multiple Myeloma Interventions:   Drug: Belantamab mafodotin;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone Sponsor:   GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Publication date: October 2019Source: Clinical Lymphoma Myeloma and Leukemia, Volume 19, Issue 10, SupplementAuthor(s): Inhwan Hwang, Dok Hyun Yoon, Cheolwon Suh, Jea-Joong kim, Chan-Jeoung Park, Jae Won Lee, Tae-Jin Yun, Sung Ho Jung, Min-Seok Kim, Heejung Chae
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: October 2019Source: Clinical Lymphoma Myeloma and Leukemia, Volume 19, Issue 10, SupplementAuthor(s): Santosh kumar Chellapuram, Lalit Kumar, raja pramanik, Aparna Sharma, Atul Sharma, Ranjit Sahoo, Prabhat singh Malik, Sunu Lazar Cyriac
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: October 2019Source: Clinical Lymphoma Myeloma and Leukemia, Volume 19, Issue 10, SupplementAuthor(s): Abdullah S. Al Saleh, M Hasib Sidiqi, Surbhi Sidana, Eli Muchtar, Angela Dispenzieri, David Dingli, Martha Lacy, Rahma Warsame, Wilson Gonsalves, Taxiarchis Kourelis, William Hogan, Suzanne Hayman, Robert Wolf, Prashant Kapoor, Francis Buadi, Shaji Kumar, Morie A. Gertz
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: October 2019Source: Clinical Lymphoma Myeloma and Leukemia, Volume 19, Issue 10, SupplementAuthor(s): Uday Yanamandra, Suman Kumar, Rajan Kapoor, Ankur Ahuja, Tathagat Chatterjee, Satyaranjan Das, Velu Nair
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: October 2019Source: Clinical Lymphoma Myeloma and Leukemia, Volume 19, Issue 10, SupplementAuthor(s): Catharina Van Elssen, Gwendolyn Van Gorkom, Lotte Wieten, Peter von dem Borne, Ellen Meijer, Gerard Bos
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: October 2019Source: Clinical Lymphoma Myeloma and Leukemia, Volume 19, Issue 10, SupplementAuthor(s): Surya Prakash Vadlamani, Lalit Kumar, raja pramanik, Ankur Nandan Varshney
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
THURSDAY, Oct. 17, 2019 -- Different racial/ethnic groups with multiple myeloma (MM) have significant variations in novel therapy and autologous stem cell transplant (ASCT) use, according to a study published online Oct. 17 in Blood...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
In conclusion, D-VMP was safe and efficacious in East Asian patients, consistent with the global ALCYONE population.
Source: Annals of Hematology - Category: Hematology Source Type: research
CONCLUSION: RD-plerixafor is an effective, safe, and affordable strategy to ensure adequate PBSC mobilization in patients with MM or lymphoma who undergo ASCT. PMID: 31618456 [PubMed - as supplied by publisher]
Source: Transfusion - Category: Hematology Authors: Tags: Transfusion Source Type: research
Continuous positive airway pressure (CPAP) is a first-line treatment for obstructive sleep apnea (OSA). However, the adherence to CPAP can be difficult for patients due to several reasons. In this case report we describe a patient with severe OSA who initially was treated successfully with CPAP, but after a few months adherence problems developed because of macroglossia. This was caused by amyloidosis due to multiple myeloma. During treatment with chemotherapy and stem cell transplantation, the size of the patient’s tongue decreased and he could successfully use his CPAP device again.Citation:van Loenhout L, van der ...
Source: Journal of Clinical Sleep Medicine : JCSM - Category: Sleep Medicine Source Type: research
More News: Dexamethasone | Myeloma | Research | Revlimid | Transplants | Velcade